Multicystic mesothelioma is an uncommon tumor mostly located in the peritoneum cavity and is particularly favored by women in their reproductive ages. Protheragen provides a broad range of multicystic mesothelioma diagnostics and therapeutics development services, including advanced preclinical research, drug discovery, therapeutic development, and diagnostic tool optimization.
Overview of Multicystic Mesothelioma
Multicystic mesothelioma is an uncommon neoplasm where the primary site is the peritoneum and is seen most often in women in their young to middle age. It is marked by the development of multiple cysts in the abdomen, particularly the pelvis. While it is commonly classified as benign, multicystic mesothelioma is difficult to manage due to its high rates of recurrence and the risk of malignant change. The etiology for the condition is unknown, and it is often diagnosed based on the histopathological findings rather than clinical or imaging clues. Although it is an uncommon condition, there is increasing interest in multicystic mesothelioma, which demonstrates its relevance in the study of mesothelioma-related cancers.
Fig.1 Pathological findings of multicystic mesothelioma. (Noiret B.,
et al., 2019)
Diagnostics Development for Multicystic Mesothelioma
- Imaging Techniques
Early diagnosis of multicystic mesothelioma often relies on imaging studies, although none are entirely conclusive in distinguishing multicystic mesothelioma from other abdominal masses. Commonly used imaging modalities include:
US is often the first diagnostic tool, providing images of multiloculated cysts filled with fluid. However, it cannot definitively distinguish multicystic mesothelioma from other cystic masses.
CT scans are used to assess the extent and location of multicystic mesothelioma, with the cysts appearing as low-density, multi-loculated, thin-walled masses. However, CT is also limited in differentiating multicystic mesothelioma from other similar abdominal masses.
Magnetic Resonance Imaging (MRI)
MRI is considered the most effective imaging tool for multicystic mesothelioma, showing hypointense lesions on T1-weighted images and hyperintense lesions on T2-weighted images. It also provides better resolution in detecting the cystic content and assessing peritoneal involvement.
- Histopathology and Immunohistochemistry
Definitive diagnosis of multicystic mesothelioma requires histological analysis, typically obtained via laparoscopy. The cysts are lined by mesothelial cells, and immunohistochemical markers such as calretinin, CK5/6, and CA125 are used to confirm the diagnosis. These markers distinguish multicystic mesothelioma from other cystic masses like lymphangioma and endometriosis.
Therapeutics of Multicystic Mesothelioma
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Chemotherapy (HIPEC) |
Cisplatin |
Alkylates DNA, causing crosslinks and preventing DNA replication, inducing apoptosis. |
Used in combination with doxorubicin during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat multicystic mesothelioma. |
Approved |
| Chemotherapy (HIPEC) |
Doxorubicin |
Intercalates into DNA, inhibiting DNA and RNA synthesis, and inducing apoptosis. |
Administered along with cisplatin in HIPEC to target malignant or borderline malignancies like multicystic mesothelioma. |
Approved |
| Hormonal Therapy |
Tamoxifen |
Antagonizes estrogen receptors, inhibiting estrogen-stimulated cell growth. |
Used as an alternative to surgery in estrogen-dependent cases, shown to reduce cyst volume. |
Approved |
| Hormonal Therapy |
GnRH Agonists |
Suppresses ovarian production of estrogen, which may reduce cyst growth in estrogen-dependent multicystic mesothelioma. |
Used as an alternative to surgery, especially for estrogen-dependent multicystic mesothelioma. |
Approved |
| Sclerotherapy |
Povidone–Iodine |
Causes local tissue sclerosis, reducing cyst size and inflammation. |
Injected directly into multicystic mesothelioma cysts to reduce size and relieve symptoms, with no recurrence in some cases. |
Approved |
| Sclerotherapy |
Ethanol |
Similar to povidone-iodine, it induces sclerosis and fibrosis within cysts. |
Used to decrease cyst diameter and alleviate symptoms in multicystic mesothelioma, also been shown to prevent recurrence. |
Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen offers comprehensive diagnostic and therapeutic development services for multicystic mesothelioma, providing cutting-edge solutions in preclinical research, diagnostics, and drug development. Our focus on multicystic mesothelioma aims to advance the understanding of this rare disease while offering innovative approaches to diagnosis and therapeutics. We support the development of tailored therapeutic solutions and cutting-edge diagnostic tools through our advanced preclinical models.
Disease Models
- Primary Cell Cultures
- Organoid Models
- Asbestos-Induced Mouse Models
- Cdkn2a/Arf Knockout Models
- Patient-Derived Xenografts (PDX)
- SV40 Virus Infection Models
At Protheragen, our preclinical research services for multicystic mesothelioma are designed to accelerate the development of new diagnostics and therapeutics. We utilize state-of-the-art animal models, cell culture systems, and advanced imaging technologies to simulate the disease in a controlled environment. These preclinical models provide valuable insights into the pathogenesis of multicystic mesothelioma and allow for the testing of new drug candidates before clinical trials, ensuring their safety and efficacy. If you are interested in our services, please feel free to contact us.
References
- Noiret, Barbara, et al. "Multicystic peritoneal mesothelioma: a systematic review of the literature." Pleura and peritoneum 4.3 (2019): 20190024.
- Zahid, A., et al. "Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy." BJS open 5.2 (2021): zraa001.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
